Showing results (1251-1260 of 3,105) with videos related to
Sort By:
Pageof 311
Drug Safety|June 23, 2022
Quantitative Prediction of Adverse Event Probability Due to Pharmacokinetic InteractionsMichel Tod, Thomas Rodier, Marine AuffretDrug Safety|June 21, 2022
Collection of Data on Adverse Events Related to Medicinal Products: A Survey Among Registries in the ENCePP Resources DatabaseKelly Plueschke, Carla Jonker, Valerie Strassmann, et al.Drug Safety|June 3, 2021
Monitoring and Managing Lorlatinib Adverse Events in the Portuguese Clinical Setting: A Position PaperFernando Barata, Carlos Aguiar, Tiago Reis Marques, et al.Drug Safety|November 18, 2020
Changes in Erythropoiesis Stimulating Agent Use Under a Risk Evaluation and Mitigation Strategy (REMS) ProgramAmeet Sarpatwari, Mengdong He, Frazer A Tessema, et al.Drug Safety|January 31, 2020
Adverse Events in Twitter-Development of a Benchmark Reference Dataset: Results from IMI WEB-RADRJuergen Dietrich, Lucie M Gattepaille, Britta Anne Grum, et al.Drug Safety|July 14, 2021
Bayesian Modeling for the Detection of Adverse Events Underreporting in Clinical TrialsYves Barmaz, Timothé MénardDrug Safety|June 13, 2021
Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010-2019Juliana Setyawan, Nassir Azimi, Vibeke Strand, et al.Drug Safety|June 15, 2021
Patient Global Impression of Benefit-Risk (PGI-BR): Incorporating Patients' Views of Clinical Benefit-Risk into Assessment of New MedicinesDaniel Eek, Katarina Halling, Emuella Flood, et al.Drug Safety|January 21, 2014
Sumatriptan-associated ischemic colitis: case report and review of the literature and FAERSThuc Quyen Nguyen, James H LewisDrug Safety|March 20, 2015
Relationship between structural alerts in NSAIDs and idiosyncratic hepatotoxicity: an analysis of spontaneous report data from the WHO databaseNaomi Jessurun, Eugene van PuijenbroekPageof 311